Top Page
Actinogen Medical
(OTC:ACW)
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Actinogen Medical Business Overview & Revenue Model
Actinogen Medical Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49M | 5.49M | 9.93M | 4.89M | 3.64M | 1.98M |
| Gross Profit | 5.29M | 5.49M | 9.93M | 4.48M | 3.24M | 1.60M |
| EBITDA | -15.01M | -15.01M | -22.53M | -15.22M | -12.72M | -5.35M |
| Net Income | -14.73M | -14.73M | -13.04M | -10.75M | -9.50M | -3.92M |
Balance Sheet | ||||||
| Total Assets | 24.48M | 24.48M | 21.31M | 15.21M | 23.31M | 18.38M |
| Cash, Cash Equivalents and Short-Term Investments | 16.50M | 16.50M | 9.45M | 8.46M | 16.37M | 13.42M |
| Total Debt | 3.26M | 3.26M | 319.07K | 86.93K | 165.27K | 236.44K |
| Total Liabilities | 6.15M | 6.15M | 1.62M | 1.80M | 1.57M | 920.32K |
| Stockholders Equity | 18.34M | 18.34M | 19.70M | 13.41M | 21.74M | 17.46M |
Cash Flow | ||||||
| Free Cash Flow | -7.59M | -7.59M | -16.96M | -8.73M | -9.52M | -1.73M |
| Operating Cash Flow | -7.56M | -7.56M | -16.95M | -8.70M | -9.52M | -1.72M |
| Investing Cash Flow | -38.02K | -38.02K | -8.16K | -36.60K | -2.94K | -6.19K |
| Financing Cash Flow | 14.65M | 14.65M | 17.95M | 824.62K | 12.42M | 10.11M |
Actinogen Medical Technical Analysis
Actinogen Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | AU$127.37M | 18.24 | 27.24% | 1.25% | 0.65% | -9.90% | |
56 Neutral | AU$44.16M | ― | -49.72% | ― | ― | 10.78% | |
54 Neutral | AU$101.62M | ― | -75.99% | ― | ― | 10.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$119.63M | ― | -42.68% | ― | ― | 63.46% | |
40 Underperform | AU$110.28M | ― | -47.98% | ― | 700.00% | 26.88% | |
34 Underperform | AU$87.50M | ― | -100.67% | ― | 1114.27% | 85.66% |
Actinogen Medical Corporate Events
Actinogen Medical announced a live webinar scheduled for October 28, 2025, where CEO Dr. Steven Gourlay and other leaders will discuss the company’s recent progress and upcoming milestones. The company is advancing its clinical trials for Xanamem, a promising therapy for Alzheimer’s Disease and Depression, with significant developments expected in 2026. This announcement highlights Actinogen’s commitment to addressing unmet medical needs in neurological and neuropsychiatric diseases, potentially impacting its market position and offering hope for stakeholders seeking new treatments.
Actinogen Medical has announced accelerated enrolment in its XanaMIA phase 2b/3 Alzheimer’s disease trial, with interim analysis scheduled for January 2026 and final results expected in mid-Q4 2026. The company also reported a successful meeting with the FDA, paving the way for a streamlined path to marketing approval and enhancing its potential for partnerships. Additionally, Actinogen has launched an Investor Hub to engage shareholders and successfully completed a pharmacokinetic trial confirming the efficacy of Xanamem’s commercial formulation. These developments signify significant progress in Actinogen’s clinical and commercial strategies, potentially strengthening its position in the Alzheimer’s treatment market.
Actinogen Medical announced that its CEO, Dr. Steven Gourlay, presented at the Canaccord Drug & Device Conference, highlighting the company’s progress with Xanamem, an oral therapy targeting brain cortisol to treat Alzheimer’s and depression. The presentation emphasized the drug’s promising clinical development, upcoming milestones, and its potential to meet the high demand for effective Alzheimer’s treatments. Actinogen’s ongoing clinical trials, including the XanaMIA Phase 2b/3 trial for Alzheimer’s and the XanaCIDD Phase 2a trial for depression, demonstrate significant benefits in managing symptoms, reinforcing Xanamem’s potential impact on the market.
Actinogen Medical has received approval for an Advance Overseas Finding, allowing them to claim an additional $1.9 million in research and development tax incentives for the 2025 financial year. This approval increases their total RDTI rebate to over $7.3 million, which will support their ongoing Alzheimer’s phase 2b/3 clinical trial. The trial is a significant step in their efforts to develop Xanamem as a treatment for Alzheimer’s, with interim results expected in January 2026 and final results in late 2026. This financial boost is crucial as the company approaches key milestones in its clinical trials, potentially strengthening its position in the biotechnology industry and offering hope for stakeholders looking for advancements in Alzheimer’s treatment.
Actinogen Medical has announced the early completion of pTau screening in its XanaMIA Alzheimer’s trial due to strong recruitment, with final results expected by mid-Q4 2026. The increased participant enrollment is set to enhance the trial’s statistical power, potentially strengthening Xanamem’s positioning as a viable oral therapy for Alzheimer’s, offering safety and efficacy advantages over existing treatments.
Actinogen Medical is advancing its revolutionary oral therapeutic, Xanamem, through pivotal trials aimed at transforming the treatment landscape for Alzheimer’s disease and major depressive disorder. This advancement reflects the company’s commitment to improving lives through precision and innovation, potentially impacting its operations and industry positioning significantly.
Actinogen Medical Limited has announced its 2025 Annual General Meeting (AGM) of Shareholders, scheduled to take place in person on November 19, 2025, at K&L Gates in Sydney. Shareholders are encouraged to lodge their proxy forms online, as hard copies of the meeting notice will not be sent unless specifically requested. This move aligns with recent legislative changes and reflects the company’s commitment to digital communication, potentially enhancing shareholder engagement and operational efficiency.
Actinogen Medical has received a $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending approval. This funding is crucial as the company progresses towards key milestones in its Alzheimer’s phase 2b/3 clinical trial, with interim results expected in January 2026 and final results in Q4 2026. The rebate supports Actinogen’s financial strategy and underscores its commitment to advancing its clinical trials, potentially strengthening its position in the biotechnology industry.
Actinogen Medical announced the date for its Annual General Meeting, set for November 19, 2025, where the re-election and appointment of directors will be discussed. The company is advancing its clinical trials for Xanamem, a promising therapy for Alzheimer’s Disease and Depression, with significant progress in its XanaMIA and XanaCIDD trials, which could impact the treatment landscape for these conditions.
Actinogen Medical Limited announced the cessation of 1,600,000 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategies and future prospects.
Actinogen Medical has reached a significant milestone by securing agreement with the FDA on the necessary steps for US marketing approval of Xanamem for Alzheimer’s disease. This includes the design of a pivotal Phase 3 trial and other clinical and nonclinical activities. The FDA’s guidance enables Actinogen to move forward confidently with its development plans and enhances its positioning for discussions with potential partners. This development aligns with global regulatory efforts to find more effective therapies for Alzheimer’s, potentially impacting stakeholders positively by advancing treatment options.
Actinogen Medical has launched a new Investor Hub to enhance engagement with shareholders, offering a centralized platform for accessing company updates and interacting with the leadership team. This initiative comes as the company approaches key milestones in its XanaMIA phase 2b/3 Alzheimer’s disease trial, with interim results expected in early 2026, potentially impacting its market position and stakeholder interests.
Actinogen Medical Limited is a biotechnology company focused on developing Xanamem, an oral therapeutic aimed at treating Alzheimer’s disease and major depressive disorder by targeting brain cortisol levels.
Actinogen Medical Limited has announced the quotation of 330,397 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective August 29, 2025. This move reflects the company’s ongoing efforts to enhance its financial position and market presence, potentially impacting its operations and stakeholder interests by increasing liquidity and investor confidence.
Actinogen Medical Limited announced the cessation of 2,000,000 ordinary fully paid securities due to a buy-back under an employee share scheme. This move could impact the company’s capital structure and reflects its ongoing efforts to manage equity distribution, potentially influencing investor perception and market positioning.
Actinogen Medical announced successful trial results for their Xanamem tablet formulation, confirming consistent therapeutic blood levels in both fed and fasted states. This supports the use of a 10 mg daily dose in ongoing trials for Alzheimer’s disease, highlighting Xanamem’s potential as a flexible and effective treatment option. The trial’s outcomes reinforce Actinogen’s position in the industry as a developer of innovative therapies for neurological conditions, potentially impacting stakeholders by advancing treatment options for Alzheimer’s and related diseases.
Actinogen Medical Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, demonstrating a commitment to transparency and accountability. This release is significant for stakeholders as it confirms the company’s compliance with governance standards, potentially enhancing investor confidence and supporting its market position.
Actinogen Medical Limited has released its Corporate Governance Statement, emphasizing its commitment to high standards of accountability and transparency. The company has adopted the ASX Corporate Governance Council’s Principles and Recommendations to the extent practical, given its size and nature. This move is seen as a fundamental step in supporting the company’s growth and ensuring effective oversight and management, which is crucial for maintaining investor confidence and positioning in the biotechnology sector.
Actinogen Medical has reported its FY2025 financial results, highlighting significant progress in its clinical trial programs for Alzheimer’s disease and major depressive disorder. The company has advanced its XanaMIA phase 2b/3 trial, with interim results expected in early 2026, and completed the XanaCIDD phase 2a trial. Actinogen has also secured substantial funding, conducted commercial readiness planning, and engaged in strategic business development activities, positioning itself for future growth and potential marketing approvals.
Actinogen Medical announced its financial results for the year ending June 30, 2025, alongside updates on its clinical trials for Xanamem, a promising therapy for Alzheimer’s Disease and Depression. The company is conducting a Phase 2b/3 trial for Alzheimer’s and a Phase 2a trial for depression, with significant progress reported, including clinically significant benefits on depression symptoms. These developments could enhance Actinogen’s position in the biotechnology industry, offering potential new treatments for debilitating cognitive and neuropsychiatric conditions.
Actinogen Medical announced that its CEO, Dr. Steven Gourlay, will present at the 2025 Bioshares Biotech Summit, discussing the company’s late-stage Alzheimer’s trial and commercialization program. The presentation will cover the progress and potential of Xanamem, a promising therapy for Alzheimer’s and Depression, highlighting the company’s confidence in trial outcomes and interest from potential partners. The ongoing XanaMIA Phase 2b/3 trial and the upcoming XanaMIA-DUR extension trial are key components of Actinogen’s strategy to establish Xanamem as a significant player in the treatment of Alzheimer’s disease, with initial results expected in 2026.
Actinogen Medical has reached a significant milestone in its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, enrolling over 100 participants and planning an interim analysis in January 2026. Additionally, the company has secured a $13.8 million R&D tax incentive funding facility and completed a scale-up batch of Xanamem tablets, positioning itself for potential commercialization and partnerships.
Actinogen Medical announced the presentation of an academic poster at the Alzheimer’s Association International Conference in Toronto, showcasing the clinical validation of Xanamem’s activity in the brain. The poster highlights the positive clinical effects of Xanamem in lowering CNS cortisol in patients with major depressive disorder, supporting its potential as a treatment for brain diseases like Alzheimer’s and depression. The company also participated in the conference with a sponsored booth, providing an opportunity to engage with healthcare professionals and discuss their late-stage clinical program and advancements in dementia research.